Monoclonal Antibody Therapeutics Market Analysis | CMI

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
MONOCLONAL ANTIBODY THERAPEUTICS MARKET ANALYSIS

• Monoclonal Antibody Therapeutics Market, by
  Source (Human, Humanized, Chimeric, and Others),
  by Therapeutic Application (Oncology, Autoimmune
  Diseases, Infectious Diseases, Hematological
  Disorders, and Others), by Distribution Channel
  (Hospital Pharmacies, Retail Pharmacies, Online
  Pharmacies, and Specialty Pharmacies), and by
  Region (North America, Latin America, Europe,
  Asia Pacific, the Middle East, and Africa) -
  Size, Share, Outlook, and Opportunity Analysis,
  2018-2026
• The global monoclonal antibody therapeutics
  market was valued at US 95,560.5 million in
  2017, and is expected to witness a robust CAGR of
  6.9 over the forecast period (20182026).

3
Market Drivers

• Increasing drug approvals and launch of novel
  monoclonal antibodies for treatment of various
  diseases such as cancer are expected to boost the
  market growth over the forecast period
• Frequent approvals of novel monoclonal antibodies
  and their launches in developed economies are
  expected to significantly drive Monoclonal
  Antibody Therapeutics Market growth over the
  forecast period. Key players in the market have
  gained regulatory approvals and have launched
  their therapies in the market. For instance, in
  2015, the U.S. FDA approved Darzalex, developed
  by Johnson Johnson for multiple myeloma.
  Similarly, in 2017, Roche was granted accelerated
  approval to TECENTRIQ (atezolizumab) from the U.S
  FDA for the treatment of people with locally
  advanced or metastatic urothelial carcinoma (mUC)
  who are not eligible for cisplatin chemotherapy.
• Moreover, approvals to several combination
  therapies are further expected to boost the
  global monoclonal antibody therapeutics market
  growth over the forecast period. For instance, in
  2017, the U.S. FDA approved Darzalex
  (daratumumab) in combination with pomalidomide
  and dexamethasone for the treatment of patients
  suffering from multiple myeloma. Moreover,
  different monoclonal antibodies with unique
  mechanism of actions have been approved over the
  past few years, which work on immune checkpoints
  such as CTLA-4, PD-1, and PD-L1.

4
Figure No.1 Global Monoclonal Antibody
Therapeutics Market Share, By Region (), 2018 -
2026
5

• Ongoing research and development of monoclonal
  antibodies for various diseases is expected to
  boost growth of the global monoclonal antibody
  therapeutics market
• Introduction and supposed success of monoclonal
  antibodies and other biological products has
  spurred the interest of manufacturers in these
  therapies. Success of popular monoclonal
  antibodies such as Avastin, Herceptin, and
  Rituxan (revenues as US 6.8 Bn, US 7.1 Bn, and
  US 5.9 Bn respectively in 2017 globally) has
  spurred manufacturers interest in these
  therapies. Leading manufacturers have resorted to
  boosting pipeline through various ways such as
  merger and acquisitions, partnerships, and
  collaboration. In 2016, AbbVie acquired
  Stemcentrx thereby adding rovalpituzumab tesirine
  (Rova-T) to its product portfolio in oncology
  segment. Cancer treatment (various types) is at
  the forefront of the monoclonal antibody research
  as leading manufacturers are focused on
  development of these drugs for cancer treatment.
  For instance, manufacturers such as Amgen, Inc.
  (e.g. Tezepelumab and others) and Novartis
  International AG (e.g. Ofatumumab and others)
  have several monoclonal antibody programs in the
  pipeline.

6
Market Restraints

• However, high costs of these products is a major
  concern (in regions with underdeveloped
  reimbursement facilities) in the healthcare
  system and to address this problem, manufacturers
  have resorted to biosimilar products. Biosimilars
  cost much lower than the original products as the
  cost of development is relatively low. Majority
  of the available monoclonal antibody therapeutics
  (cancer treatments) are expected to lose patent
  protection by 2020 and some by 2025. For
  instance, drugs such as Herceptin and Avastin are
  expected to lose patent protection in 2019. These
  factors are expected to restrain the global
  monoclonal antibody therapeutics market growth
  over the forecast period.

7
Key Players

• Some of the major players operating in the global
  monoclonal antibody therapeutics market include,
  Pfizer, Inc., Novartis International AG, Amgen,
  Inc., Sanofi S.A., Merck Co., Inc.,
  GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd.,
  AbbVie, Inc., Eily, Lilly, and Company, and
  Bristol-Myers Squibb Company.

8

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Reference https//www.coherentmarketinsights.com
  /market-insight/monoclonal-antibody-therapeutics-m
  arket-2403

9
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

10
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

11

• Thank You!
• Kindly follow CMI Social Media Profiles
  for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/